SCHEMBL3303329

SCHEMBL3303329

Cc1ccccc1-n1ncc(-c2ccc3nccnc3c2)c1N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 7/20 0.58
NPC1 O15118 6/20 0.45
RAB9A P51151 6/20 0.45
KMT2A Q03164 3/20 0.45
MAPK14 Q16539 2/20 0.43
MAPT P10636 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGDS O60760 1/20 0.43
GAA P10253 1/20 0.43
ADORA2B P29275 1/20 0.41
LCK P06239 1/20 0.40
KDR P35968 1/20 0.40
JAK3 P52333 1/20 0.40
ADORA3 P0DMS8 1/20 0.39
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
TGFBR1 P36897 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28790507 0.83 ADORA1 (0.42) ADORA1NPC1RAB9AKMT2AMAPT
SCHEMBL1817276 0.82 RAB9A (0.63) ADORA1NPC1RAB9AKMT2AMAPT
SCHEMBL3305577 0.78 ADORA1 (0.58) ADORA1NPC1RAB9AKMT2AMAPT
SCHEMBL3306156 0.74 ADORA1 (1.00) ADORA1ADORA2BADORA3TGFBR1
SCHEMBL1817013 0.73 ADORA1 (0.81) ADORA1MAPK14ADORA2BADORA3TGFBR1
SCHEMBL27751914 0.73 CLK4 (0.55) ADORA1KMT2AMAPK14ALDH1A1LCK
SCHEMBL3251762 0.70 MAPK14 (0.57) NPC1RAB9AKMT2AMAPK14MAPT
Hydrochloric Acid SCHEMBL5402695 0.69 MAPK14 (0.56) NPC1RAB9AKMT2AMAPK14MAPT
SCHEMBL1815226 0.68 MAPK14 (0.55) NPC1RAB9AKMT2AMAPK14MAPT
SCHEMBL23398518 0.66 NPC1 (0.49) ADORA1NPC1RAB9AKMT2AMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
WO-2010020363-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF CYP3A5, ABAT, TPMT ADORA1 724/4885NPC1 3065/4885RAB9A 3316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.